**Pharmaceutical Products:** 70%
**Health Products:** 20%
**Research and Development:** 10%

**TOP 3 Markets:**
**South Korea:** 50%
**USA:** 30%
**Japan:** 10%

Bukwang Pharmaceutical Co., Ltd. generates the majority of its revenue from pharmaceutical products, accounting for approximately 70% of total revenue. These include both prescription drugs and over-the-counter products.

The domestic market of South Korea is the largest market for Bukwang, followed by the USA, which has a significant share due to the strong demand for innovative pharmaceutical solutions. Japan represents the third largest market, attributed to strategic partnerships and adaptation to local needs.

**Production Sites:** Headquarters in Seoul, South Korea; Production facilities in Ansan, South Korea.

Bukwang Pharmaceutical Co., Ltd. mainly produces its pharmaceutical products in South Korea. The company's headquarters are located in Seoul, while the main production activities take place at the facilities in Ansan. These sites enable the company to efficiently serve both the domestic market and international markets.

**Focus on Research and Development:** 15% of revenue (2025)

**Expansion of International Markets:** Goal: 20% revenue share from overseas by 2027

Bukwang Pharmaceutical Co., Ltd. is strongly committed to research and development by investing 15% of its revenue in this area. This demonstrates the company's dedication to developing innovative drugs and expanding its product pipeline.

Another strategic focus is on expanding into international markets. The company aims to generate 20% of its revenue from overseas markets by 2027. This strategy includes partnerships with foreign companies and adapting their products to meet local market requirements.

Additionally, Bukwang plans to strengthen its market presence and explore new growth opportunities through strategic alliances and acquisitions.

**Main raw materials:** Active pharmaceutical ingredients (APIs), excipients

**Countries of origin:** China, India, Germany

Bukwang Pharmaceutical Co., Ltd. mainly imports active pharmaceutical ingredients (APIs) and excipients needed for the production of their medications. China and India are the leading suppliers for APIs, as these countries have strong production capacities and cost-effective manufacturing processes. Germany is often sourced for specific, high-quality pharmaceutical materials used in specialized medications.

This import strategy enables Bukwang Pharmaceutical to produce both high-quality and cost-effective products to remain competitive in the global market.

**Market Share:** Estimated 5-7% in the South Korean pharmaceutical market (2026)

**R&D Expenses:** 12% of revenue (2025)

Bukwang Pharmaceutical Co., Ltd. has a moderate competitive advantage in the South Korean pharmaceutical market. The company heavily invests in research and development, accounting for about 12% of its revenue. These investments enable Bukwang to develop innovative products and position itself in niche markets.

The estimated market share of 5-7% indicates that Bukwang plays a significant, but not dominant role in the market. The competitive advantage is strengthened by the company's ability to develop new drugs and improve existing product lines.

However, Bukwang operates in a fiercely competitive market environment with both local and international companies. To further enhance its competitive advantage, Bukwang could benefit from strategic partnerships and increased international expansion.

**Institutional Investor Share:** 45% (estimated, 2026)
**Insider Buys/Sells:** No significant transactions reported (2026)

The institutional investor share in Bukwang Pharmaceutical Co., Ltd. is estimated to be around 45%. This indicates a strong interest from institutional investors, reflecting confidence in the company's strategy and management.

In 2026, no significant insider buys or sells were reported. This could suggest that the management has confidence in the current valuation of the company or does not expect any significant changes in the company's strategy.

**Market share of Bukwang Pharmaceutical Co., Ltd.:** Estimate: 2-3% (2026)

**Top competitors by market share:**
1. **Samsung Biologics** - 15%
2. **Celltrion** - 12%
3. **Hanmi Pharmaceutical** - 10%
4. **Yuhan Corporation** - 8%
5. **Green Cross Corporation** - 7%
6. **LG Chem Life Sciences** - 6%
7. **Daewoong Pharmaceutical** - 5%
8. **Bukwang Pharmaceutical Co., Ltd.** - 2-3%

Bukwang Pharmaceutical Co., Ltd. has a relatively small market share compared to the industry's leading companies. The biggest competitors, such as Samsung Biologics and Celltrion, dominate the market with double-digit market shares. These companies benefit from significant investments in research and development as well as a strong international presence.

Bukwang Pharmaceutical's moat is less pronounced compared to its larger competitors. While Bukwang has a solid product pipeline and niche products, the larger companies like Samsung Biologics and Celltrion have significant advantages in terms of economies of scale, global reach, and extensive partnerships.

Competing companies have a stronger moat due to their size, innovation capabilities, and strategic alliances. Bukwang would need to invest in strategic partnerships and innovations to strengthen its competitive position and expand its moat.

**Revenue Growth:** 8.5% (2025)
**Research and Development Ratio:** 12% of revenue (2025)
**Market Share in the Asian pharmaceutical market:** 3% (2025)

Bukwang Pharmaceutical Co., Ltd. achieved a revenue growth of 8.5% in 2025, attributed to successful expansion into new markets and the introduction of new products. The focus on research and development, with an investment ratio of 12% of revenue, demonstrates the company's commitment to innovation and long-term growth.

The 3% market share in the Asian pharmaceutical market indicates a solid position that could be further strengthened through strategic partnerships and product diversification. Given these factors, Bukwang Pharmaceutical could be an attractive investment for investors looking for sustainable growth and innovation.

However, it is important to monitor general market conditions and potential risks, such as regulatory changes or competitive pressure.

**Dividend payment:** Yes, Bukwang Pharmaceutical Co., Ltd. pays a dividend.
**Dividend yield:** Approx. 1.5% (estimated for 2026 based on historical data)
**Reliability of payout:** Moderate

Bukwang Pharmaceutical has paid a dividend in recent years, although the level of the dividend yield has varied. The reliability of the payout can be considered moderate, as the company has adjusted the dividend in some years in the past, depending on financial performance and investment needs.

Bukwang Pharmaceutical's dividend policy seems to aim at returning a portion of profits to shareholders while also providing enough funds for research and development as well as other strategic investments. Analysts should consider the company's financial stability and future earnings forecasts to better assess the sustainability of dividend payments.